Catalyst Pharmaceuticals Inc CPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
-
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
-
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
-
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
-
These small-cap stocks score highest when screened for quality
-
These small-cap stocks score highest when -2-
-
20 companies screened for quality in a cheap part of the stock market
Trading Information
- Previous Close Price
- $19.95
- Day Range
- $19.53–20.02
- 52-Week Range
- $11.55–21.67
- Bid/Ask
- $17.01 / $19.56
- Market Cap
- $2.32 Bil
- Volume/Avg
- 799,643 / 998,278
Key Statistics
- Price/Earnings (Normalized)
- 35.35
- Price/Sales
- 5.35
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 167
- Website
- https://www.catalystpharma.com
Comparables
Valuation
|
Metric
|
CPRX
|
HRTX
|
CRMD
|
|---|---|---|---|
Price/Earnings (Normalized) | 35.35 | — | — |
Price/Book Value | 3.81 | — | 9.63 |
Price/Sales | 5.35 | 2.25 | 572.38 |
Price/Cash Flow | 12.06 | — | — |
Price/Earnings
CPRX
HRTX
CRMD
Financial Strength
|
Metric
|
CPRX
|
HRTX
|
CRMD
|
|---|---|---|---|
Quick Ratio | 4.69 | 1.76 | 4.12 |
Current Ratio | 5.14 | 2.38 | 4.79 |
Interest Coverage | — | — | −1,599.40 |
Quick Ratio
CPRX
HRTX
CRMD
Profitability
|
Metric
|
CPRX
|
HRTX
|
CRMD
|
|---|---|---|---|
Return on Assets (Normalized) | 43.35% | −11.68% | −66.44% |
Return on Equity (Normalized) | 50.92% | — | −77.20% |
Return on Invested Capital (Normalized) | 50.52% | −18.15% | −81.35% |
Return on Assets
CPRX
HRTX
CRMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Pmqynhmk | Ntbn | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ywlqjqrtm | Cwgmng | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dpjnnmzhd | Hzzstj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tlctkgtw | Lgqphjh | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Xmnkynmdq | Rfqb | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Nfthyflm | Crphq | $28.1 Bil | |||
| Moderna Inc
MRNA
| Tcsycgnb | Jqlvq | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Zkbqxvnt | Kbdn | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wxcjvby | Vsdnn | $13.4 Bil | |||
| Incyte Corp
INCY
| Scvjnttj | Ywpkp | $12.7 Bil |
United States